Compare AGCO & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGCO | GKOS |
|---|---|---|
| Founded | 1990 | 1998 |
| Country | United States | United States |
| Employees | 22000 | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.0B |
| IPO Year | 1994 | 2015 |
| Metric | AGCO | GKOS |
|---|---|---|
| Price | $120.97 | $153.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $119.09 | ★ $126.92 |
| AVG Volume (30 Days) | 625.6K | ★ 692.4K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | ★ 271.35 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $10,082,000,000.00 | $507,442,000.00 |
| Revenue This Year | $6.52 | $23.32 |
| Revenue Next Year | $5.56 | $27.43 |
| P/E Ratio | $154.30 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $99.21 | $73.16 |
| 52 Week High | $143.78 | $161.53 |
| Indicator | AGCO | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 61.97 |
| Support Level | $109.31 | $96.44 |
| Resistance Level | $121.00 | $161.53 |
| Average True Range (ATR) | 3.42 | 5.46 |
| MACD | 0.46 | -0.85 |
| Stochastic Oscillator | 98.37 | 55.40 |
Agco is a global manufacturer of agricultural equipment. Its main machine brands are Fendt, Massey Ferguson, and Valtra; its initiatives in precision agriculture have been organized under the PTx umbrella following a series of acquisitions. While a global business, Agco's sales skew heavily toward Europe/Middle East, representing 50%-60% of sales and even more of operating profits. The company is trying to increase its exposure to the larger North and South American markets. Its products are available through a global dealer network, which includes over 3,000 dealers and distribution locations and reaches into over 140 countries. Additionally, Agco offers retail and wholesale financing to customers through its partnership with Rabobank of the Netherlands, having exited their JV in 2026.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.